Page 1

SARTORIUS Earnings Release Göttingen , April 21 , 2021 Sartorius with first - quarter uptick in sales and earnings Order intake up 89.2 percent ; sales revenue up 61.6 percent ; underlying EBITDA margin 33.3 percent 20 percentage points of sales growth influenced by the coronavirus pandemic Accelerated expansion of production capacities in all regions on track as planned The life science group Sartorius had an exceptionally strong start in fiscal 2021 and grew substantially in order intake , sales revenue and earnings . Businesses related to the coronavirus pandemic additionally fueled this growth . " Many of our products play an essential role in helping to overcome the pandemic . In addition to a very positive general business performance in the first quarter , we accordingly experienced strong demand for our products and technologies used in the development and production of vaccines as well as of coronavirus tests and achieved a sharp increase in sales . The substantial rise in the company's profit margin was also supported by underproportionate development of costs , such as the low number of business trips as well as fewer new hires in non - production areas . These effects are expected to decrease as the year progresses . In many areas , we are working at the limits of our capacity and are therefore continuing to move ahead with accelerating the expansion of our production facilities and are hiring additional employees , " said Executive Board Chairman and CEO Joachim Kreuzburg . In the first three months of the current year , Sartorius has already created some 640 new jobs ; the Group now employs around 11,300 people in total . Business development of the Group Group sales revenue surged by 61.6 percent to around 791 million euros in constant currencies ( reported : +55.1 percent ) . The comparative base for these high growth figures , though , is the relatively low prior - year quarter , which was impacted in the Lab Products & Services Division by the lockdown in China due to the pandemic and overall did not yet include an acquisition that was consolidated as of May 2020. In the first quarter , acquisitions² contributed overall about 12 percentage points to growth while the contribution attributable to businesses related to the coronavirus pandemic was about 20 percentage points . Order intake¹ ' grew even more dynamically than sales revenue , rising to 1,139 million euros ( in constant currencies : +89.2 percent , of which a good 30 percentage points were related to the coronavirus ; reported : +80.9 percent ) . Underlying EBITDA¹ climbed , due to economies of scale and underproportionate cost development , to 264 million euros , up from 138 million euros a year earlier ( +91.2 percent ) . The corresponding margin rose to 33.3 percent ( Q1 2020 : 27.0 percent ) . Relevant net profit¹ for the Group soared by 111.8 percent to 122 million euros ; earnings per ordinary share were 1.77 euros ( Q12020 : 0.83 euros ) ; earnings per preference share , 1.78 euros ( Q1 2020 : 0.84 euros ) . 1 | 10